analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
Published 3 years ago • 109 plays • Length 2:07Download video MP4
Download video MP3
Similar videos
-
3:00
the promise of momelotinib in the treatment of myelofibrosis
-
14:25
an overview of novel innovative treatments for patients with von willebrand disease
-
3:03
an insight into the momentum trial: safety and efficacy of momelotinib for the treatment of mf
-
2:28
long-term momelotinib exposure in jaki-naïve or previously jaki-treated myelofibrosis patients
-
2:16
long-term safety of momelotinib for myelofibrosis
-
1:53
recent updates from the momentum trial and the value of momelotinib for the treatment of mf
-
1:26
updates on the use of momelotinib for the treatment of mf & clinical trials evaluating this agent
-
2:20
momentum & the potential impact of approval of momelotinib in myelofibrosis
-
2:44
myelofibrosis: jenson shares his experience
-
4:49
myelofibrosis - causes, symptoms, diagnosis, treatment, pathology
-
3:22
jak2 inhibition in the treatment of myelofibrosis
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
2:04
introducing a phase ib/ii trial to evaluate tasquinimod for the treatment of myelofibrosis
-
3:48
efficacy of momelotinib in thrombocytopenic patients with myelofibrosis from momentum
-
1:40
momelotinib for the treatment of myelofibrosis
-
1:52
an update on the use of navtemadlin in myelofibrosis
-
4:25
update on momelotinib for myelofibrosis
-
3:46
an update on the summit trial: bezuclastinib in non-advanced systemic mastocytosis
-
1:19
single-cell sequencing of circulating tumor cells to predict progression from mgus/smm
-
2:33
optimizing current treatment approaches in myelofibrosis
-
1:15
ongoing trials of ruxolitinib, momelotinib and imetelstat in myelofibrosis
-
0:42
talquetamab treatment in patients with r/r myeloma with prior exposure to t-cell-directed therapies